1. A2.20 ICOS-ICOSL interaction regulates lymphotoxin alpha expression and maturation of lymphoid-like stromal cells during inflammation. (13th February 2015) Authors: Campos, J; Nayar, S; Chung, M; Hitchcock, JR; Withers, DR; Cunningham, AF; Carlesso, G; Herbst, R; Buckley, CD; Barone, F Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0331 A novel humanized effector-deficient fcyriia antibody inhibits immune complex mediated proinflammatory responses. (15th June 2017) Authors: Chen, B; Vousden, K; Turman, S; Sun, H; Wang, S; Vinall, L; Kemp, B; Kasturiangan, S; Grant, E; Hinrichs, MJ; Eck, S; DiGiandomenico, A; Xiong, X; Griffiths, J; Herbst, R; Close, D; Kolbeck, R; Sims, G Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SO-002Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). (2nd July 2019) Authors: Chau, I; Bendell, J; Soriano, A; Arkenau, H; Cultrera, J; Santana-Davila, R; Calvo, E; Tourneau, C Le; Zender, L; Mi, G; Schelman, W; Ferry, D; Herbst, R; Fuchs, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗